v3.26.1
Variable Interest Entities (Additional Information) (Details)
$ / shares in Units, ₩ in Billions
 3 Months Ended 6 Months Ended
Dec. 05, 2025
USD ($)
$ / shares
shares
Apr. 17, 2025
USD ($)
$ / shares
shares
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
Jun. 30, 2026
KRW (₩)
shares
May 22, 2026
$ / shares
Mar. 02, 2026
$ / shares
Dec. 31, 2025
USD ($)
$ / shares
shares
Jun. 11, 2024
shares
Variable Interest Entity [Line Items]                      
Preferred Stock, Par or Stated Value Per Share | $ / shares     $ 0.0001   $ 0.0001         $ 0.0001  
Common stock, shares issued | shares     8,493,000   8,493,000   8,493,000     8,491,267 3,250,000
Common stock, par value | $ / shares     $ 0.0001   $ 0.0001     $ 0.0001 $ 0.68 $ 0.0001  
Ownership Interest Rate   60.00%                  
Net income for Scilex Bio attributable to the noncontrolling interest     $ (1,486,000) $ (1,740,000) $ (3,866,000) $ (1,740,000)          
Cash and cash equivalents     566,000   566,000         $ 4,955,000  
Property and equipment, net     12,766,000   12,766,000         13,599,000  
Inventory     4,171,000   4,171,000         $ 4,789,000  
PA OPS Investor LLC [Member]                      
Variable Interest Entity [Line Items]                      
Equity Investment     $ 1,500,000   $ 1,500,000            
VIE [Member]                      
Variable Interest Entity [Line Items]                      
Equity Method Investment, Ownership Percentage     60.00%   60.00%   60.00%        
Vivasor [Member]                      
Variable Interest Entity [Line Items]                      
Preferred Stock, Shares Issued | shares 6,101,468                    
Equity Method Investment, Ownership Percentage 32.60%                    
Net income for Scilex Bio attributable to the noncontrolling interest     $ 600,000   $ 2,100,000            
Cash and cash equivalents     500,000   500,000            
Short term debt     39,900,000   39,900,000            
Property and equipment, net     12,000,000   12,000,000            
Inventory     3,900,000   3,900,000            
Datavault License     20,000,000   20,000,000            
Investment In Datavault     15,300,000   15,300,000            
Accounts Payable     37,000,000   37,000,000            
Accrued Expenses     9,500,000   9,500,000            
NeuroBioGen Company [Member]                      
Variable Interest Entity [Line Items]                      
Aggregate amount payable under license agreements     4,800,000,000   4,800,000,000            
EAR SPV [Member] | Vivasor [Member]                      
Variable Interest Entity [Line Items]                      
Preferred Stock, Par or Stated Value Per Share | $ / shares $ 0.00001                    
Payments to Acquire Businesses, Gross $ 9,000,000                    
Scilex Bio JV [Member]                      
Variable Interest Entity [Line Items]                      
Common stock, shares issued | shares   5,000,000                  
Ownership Interest Rate   40.00%                  
Historical carrying value of semnur shares   $ 0                  
Percentage of estimated fair value expensed as in-process research and development   40.00%                  
Estimated fair value expensed as in-process research and development net   $ 9,400,000                  
In process research and development amount of estimated fair value   4,900,000                  
Initial upfront payment due under the licensing arrangement recognised as current liability   1,100,000                  
Additional paid-in capital as capital contribution   $ 1,800,000                  
Net income for Scilex Bio attributable to the noncontrolling interest     $ 6,300   $ 28,700            
Aggregate amount payable under license agreements | ₩             ₩ 6,500.0        
Upfront fee payable under license agreement | ₩             1.5        
Upfront fee payable under license agreement contingent upon the achievement of specified development, regulatory, and commercial milestone | ₩             ₩ 68.5        
Percentage of royalties on sales payable until expiration of licensed patent     5.00%   5.00%   5.00%        
Aggregate amount payable under license agreements capped amount | ₩             ₩ 6,500.0        
Upfront fee payable first tranche. | ₩             ₩ 1.5        
Accrued Expenses     $ 1,100,000   $ 1,100,000            
Scilex Bio JV [Member] | NeuroBioGen Company [Member]                      
Variable Interest Entity [Line Items]                      
Upfront fee payable under license agreement     1,100,000   1,100,000            
Upfront fee payable under license agreement contingent upon the achievement of specified development, regulatory, and commercial milestone     50,700,000   50,700,000            
Aggregate amount payable under license agreements capped amount     4,800,000,000   4,800,000,000            
Upfront fee payable first tranche.     1,100,000   1,100,000            
Scilex Bio JV [Member] | Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]                      
Variable Interest Entity [Line Items]                      
Common stock, par value | $ / shares   $ 0.00001                  
Semnur [Member]                      
Variable Interest Entity [Line Items]                      
Net income for Scilex Bio attributable to the noncontrolling interest     900,000   1,700,000            
Cash and cash equivalents     39,000,000   39,000,000            
Property and equipment, net     700,000   700,000            
Accounts Payable     6,900,000   6,900,000            
Accrued Expenses     1,300,000   1,300,000            
Notes Payable     $ 2,100,000   $ 2,100,000